ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design

PURPOSE: IDegAsp, a co-formulation of long-acting basal (insulin degludec) and rapid-acting bolus (insulin aspart) insulin, provides separate prandial and basal glucose-lowering effects with relatively low risk of hypoglycaemia. Its efficacy and safety have been investigated in a large clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Fulcher, Gregory R., Jarlov, Henrik, Piltoft, Johanne Spanggaard, Singh, Kiran Pal, Liu, Lei, Mohamed, Mafauzy, Nicodemus, Nemencio Almare, Al-Jaser, Saleh Jaser, Kok, Adri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Endocrine Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506473/
https://www.ncbi.nlm.nih.gov/pubmed/34637072
http://dx.doi.org/10.1007/s12020-021-02887-8

Ejemplares similares

Ejemplares similares